In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
The European Commission has approved the use of Perjeta (pertuzumab) from Swiss drug major Roche in combination with Herceptin (trastuzumab) and chemotherapy. 31 July 2015
Japanese drug major Eisai on Friday said it has partnered with Halozyme Therapeutics for early stage combination drug trial to treat advanced breast cancer. 31 July 2015
Ligand Pharmaceuticals has entered into a global license and supply agreement with French pharma major Sanofi to utilize Captisol in the development and commercialization of SAR-125844 30 July 2015
Malaysian biotechnology firm Bioven, which is conducting Phase III clinical trials on a promising vaccine against cancer made in Cuba, wants to create and finance a quoting office in London after a fruitful collaboration with Cuba, reports the Prensa Latina news agency. 30 July 2015
Anglo-Swedish drug major AstraZeneca on Thursday posted a 2% rise in second-quarter revenue ahead of estimates as the company continues heavy investment in research and development of new product pipeline. 30 July 2015
Japanese drugmaker Kyowa Hakko Kirin and USA pharma major Bristol-Myers Squibb have entered into a clinical trial collaboration agreement to conduct a Phase I/II combination study with mogamulizumab, an anti-CCR4 antibody and Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor. 30 July 2015
Ariad Pharmaceuticals says it will receive $100 million in cash – $50 million upon deal execution late yesterday and an additional $50 million in one year – through a synthetic-royalty financing from PDL BioPharma. 29 July 2015
Boehringer Ingelheim and South Korean drugmaker Hanmi Pharmaceutical have entered into an exclusive license and collaboration agreement for the development and commercialization of HM61713, a novel third-generation EGFR targeted therapy for the treatment of EGFR mutation-positive lung cancer. 29 July 2015
Pharma giant Merck & Co on Tuesday said it has agreed to buy Israel-based drugmaker cCAM Biotherapeutics for as much as $605 million in a bid to expand its immuno-oncology portfolio. 29 July 2015
A government survey has revealed American spending on prescription drug jumped 12.6% in 2014 to $305.1 billion, compared with 2.5% a year ago based on increased spending on new hepatitis C treatments and drugs for cancer and multiple sclerosis. 29 July 2015
Swiss pharma giant Roche’s atezolizumab is poised to become a major bladder cancer therapy in the race for US Food & Drug Administration approval, following its promising performance in recent Phase II trials. 29 July 2015
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment to Japan’s largest drugmaker Takeda Pharmaceutical’s ixazomib. 28 July 2015
Teva Parenteral Medicines, a unit of Israeli generics giant Teva Pharmaceuticals Industries, has voluntarily recalled six lots of Adrucil (fluorouracil injection, USP) 5g/100 mL (50mg/mL), the US Food and Drug Administration announced yesterday. 28 July 2015
French pharma major Sanofi has entered into a new global collaboration with long-time partner US biotech firm Regeneron to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. 28 July 2015
Japan’s Fujifilm Kyowa Kirin Biologic has entered into an agreement with Anglo-Swedish pharma major AstraZeneca to establish a joint venture for the development and commercialization of FKB238 in development for the treatment of multiple solid tumors. 27 July 2015
Germany-based BioMed X Innovation Center has extended its collaboration with Merck Serono, the biopharmaceuticals business of Merck KGaA, on new approaches for cancer therapy. 27 July 2015
A dose of aromatase inhibitors and bisphosphonates can potentially reduce the risk of mortality in postmenopausal women with early breast cancer, a recent study has found. According to a report published in The Lancet, a combination of the two drugs classes may also increase the benefits while cutting down some side effects. 27 July 2015
The US Food and Drug Administration approved Swiss pharma giant Novartis’ Odomzo (sonidegib, formerly LDE225) 200mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC). 26 July 2015
There was good news on Friday for Swiss pharma giant Novartis, with positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), one for a melanoma treatment and other for a blood disorder drug. 24 July 2015
Specialist cancer diagnostic medtech company Angle PLC says its loss for the financial year was “deliberate” as it posted a loss from continuing operations of £3.9 million ($6 million). 24 July 2015